Perrigo Company(the "Company") traces its history back to 1887. What was started as a small local proprietor selling medicinals to regional grocers has evolved into a leading global pharmaceutical company that manufactures and distributes more than 47 billion oral solid doses and more than two billion liquid doses, as well as dozens of other product forms, each year. The Company's mission is to offer "Quality, Affordable Healthcare ProductsTM", and it does so across a wide variety of product categories primarily in the United States("U.S."), United Kingdom("U.K."), Mexico, Israeland Australia, and distributes into dozens of other markets around the world, including Canada, Chinaand Latin America. Segments - The Company has four reportable segments, aligned primarily by type of product: Consumer Healthcare, Nutritionals, Rx Pharmaceuticalsand API. In addition, the Company has an Other category that consists of the IsraelPharmaceutical and Diagnostic Products operating segment, which does not individually meet the quantitative thresholds required to be a separately reportable segment.
manufacturer of over-the-counter ("OTC") pharmaceutical products. Major
product categories include analgesics, cough/cold/allergy/sinus,
gastrointestinal, smoking cessation, animal health, and secondary product
categories include feminine hygiene, diabetes care and dermatological
care. The CHC business markets products that are comparable in quality and effectiveness to national brand products.The cost to the retailer of a store brand product is significantly lower than that of a comparable nationally advertised brand-name product. Generally, the retailers' dollar profit per unit of store brand product is greater than the dollar profit per unit of the comparable national brand product. The retailer, therefore, can price a store brand product below the competing national brand product and realize a greater profit margin. The consumer benefits by receiving a high quality product at a price below the comparable national brand product. Therefore, the Company's business model saves consumers on their healthcare spending. The Company, one of the original architects of private label pharmaceuticals, is the market leader for consumer healthcare products in many of the geographies where it currently competes - the U.S.,
U.K., and Mexico- and is developing its position in Australia. The Company's market share of OTC store brand products has grown in recent years as new products, retailer efforts to increase consumer education and awareness, and economic conditions have directed consumers to the value of store brand product offerings.